A new study identifies how the molecule, called ApoM, can clear harmful cholesterol deposits linked to macular degeneration ...

A new study reveals that increasing levels of apolipoprotein M (ApoM) may slow or prevent the progression of age-related macular degeneration (AMD), a major cause of blindness in older adults.

Belite Bio has completed enrolment in the 24-month PHOENIX Phase III trial assessing the tolerability and safety of oral ...

New findings reveal RG6501 cell therapy shows promising long-term visual improvements for geographic atrophy patients ...

Yesafili, a biosimilar to Eylea, received Health Canada's approval, marking the first such approval in Canada. Indicated for ...

The new branding showcases the Company's innovative vision for the future and mission to redefine the retina experience ...

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...

CHENNAI: Biocon Biologics, the biosimilars subsidiary of Biocon Ltd, said on Friday that Health Canada has granted a Notice ...

Findings could help explain the links between macular degeneration and cardiovascular disease, which both worsen with age.

Canadian study reveals diabetic patients taking GLP-1 medications face twice the risk of eye problems, with longer exposure ...